CTMX RSI Chart
Last 7 days
-4.5%
Last 30 days
7.4%
Last 90 days
28.6%
Trailing 12 Months
4.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 119.2M | 0 | 0 | 0 |
2023 | 67.6M | 79.5M | 94.7M | 101.2M |
2022 | 38.2M | 42.2M | 44.2M | 53.2M |
2021 | 29.7M | 31.5M | 33.3M | 37.3M |
2020 | 74.9M | 72.9M | 69.6M | 68.4M |
2019 | 74.8M | 62.5M | 60.7M | 57.5M |
2018 | 74.2M | 86.7M | 75.1M | 59.5M |
2017 | 24.5M | 30.1M | 50.8M | 71.6M |
2016 | 8.2M | 9.2M | 10.8M | 15.0M |
2015 | 6.2M | 7.6M | 7.6M | 7.7M |
2014 | 1.9M | 3.0M | 4.0M | 5.1M |
2013 | 0 | 0 | 0 | 888.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 26, 2024 | mccarthy sean a. | acquired | 172,874 | 1.5749 | 109,768 | ceo |
Mar 19, 2024 | rowland lloyd a | sold | -10,986 | 2.0855 | -5,268 | general counsel |
Mar 19, 2024 | landau jeffrey b | sold | -13,685 | 2.0855 | -6,562 | chief business officer |
Mar 19, 2024 | ogden christopher | sold | -6,196 | 2.0855 | -2,971 | svp, finance and accounting |
Mar 19, 2024 | mccarthy sean a. | sold | -42,175 | 2.0855 | -20,223 | ceo |
Mar 19, 2024 | belvin marcia | sold | -26,684 | 2.0855 | -12,795 | svp, chief scientific officer |
Jan 18, 2024 | chu yu-waye | acquired | - | - | 26,250 | chief medical officer |
Jan 18, 2024 | rowland lloyd a | acquired | - | - | 25,000 | general counsel |
Jan 18, 2024 | mccarthy sean a. | acquired | - | - | 90,000 | ceo |
Jan 18, 2024 | belvin marcia | acquired | - | - | 26,250 | svp, chief scientific officer |
Which funds bought or sold CTMX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 528 | 355,251 | 400,571 | -% |
May 16, 2024 | Tidal Investments LLC | reduced | -5.88 | 156,475 | 630,941 | 0.01% |
May 15, 2024 | Squarepoint Ops LLC | added | 39.6 | 224,803 | 458,129 | -% |
May 15, 2024 | ADAGE CAPITAL PARTNERS GP, L.L.C. | new | - | 4,360,000 | 4,360,000 | 0.01% |
May 15, 2024 | Schonfeld Strategic Advisors LLC | new | - | 2,778,420 | 2,778,420 | 0.02% |
May 15, 2024 | Laurion Capital Management LP | reduced | -30.14 | -29,650 | 1,665,930 | 0.01% |
May 15, 2024 | TWO SIGMA ADVISERS, LP | added | 256 | 256,164 | 320,024 | -% |
May 15, 2024 | Sio Capital Management, LLC | new | - | 3,484,930 | 3,484,930 | 1.04% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -1.53 | 3,908,500 | 14,061,000 | 1.46% |
May 15, 2024 | Brevan Howard Capital Management LP | new | - | 39,362 | 39,362 | -% |
Unveiling CytomX Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to CytomX Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
CytomX Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 55.8% | 41,463,000 | 26,607,000 | 26,384,000 | 24,724,000 | 23,499,000 | 20,123,000 | 11,147,000 | 12,853,000 | 9,040,000 | 11,132,000 | 9,189,000 | 8,795,000 | 8,197,000 | 7,078,000 | 7,466,000 | 6,988,000 | 46,895,000 | 8,279,000 | 10,712,000 | 9,013,000 | 29,485,000 |
Operating Expenses | 9.5% | 29,806,000 | 27,213,000 | 23,261,000 | 28,072,000 | 29,152,000 | 29,631,500 | 40,857,000 | 42,907,000 | 41,102,000 | 46,035,000 | 40,228,000 | 35,493,000 | 31,598,000 | 31,152,000 | 32,683,000 | 32,746,000 | 52,386,000 | 45,658,000 | 36,430,000 | 40,246,000 | 46,050,000 |
S&GA Expenses | -100.0% | - | 7,827,000 | 6,813,000 | 7,401,000 | 7,977,000 | 10,067,500 | 10,490,000 | 11,748,000 | 10,543,000 | 9,455,000 | 11,085,000 | 9,393,000 | 9,227,000 | 9,145,000 | 8,634,000 | 8,680,000 | 9,572,000 | 9,217,000 | 8,463,000 | 9,411,000 | 9,674,000 |
R&D Expenses | 13.8% | 22,052,000 | 19,386,000 | 16,448,000 | 20,671,000 | 21,175,000 | 19,564,000 | 30,367,000 | 31,159,000 | 30,559,000 | 36,580,000 | 29,143,000 | 26,100,000 | 22,371,000 | 22,007,000 | 24,049,000 | 24,066,000 | 42,814,000 | 36,441,000 | 27,967,000 | 30,835,000 | 36,376,000 |
EBITDA Margin | 455.0% | 0.15 | -0.04 | -0.33 | -0.84 | -0.99 | -1.80 | -2.75 | -2.92 | -3.16 | -3.00 | -3.04 | -3.02 | -3.15 | - | - | - | - | - | - | - | - |
Income Taxes | -95.4% | 49,000 | 1,069,000 | 2,823,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | -13,911,000 | -421,000 | - | - | -6,000 |
Earnings Before Taxes | 626.1% | 13,840,000 | 1,906,000 | 5,815,000 | - | -3,311,000 | -8,775,500 | -29,064,000 | -29,496,000 | -31,981,000 | -34,823,000 | -30,982,000 | -26,736,000 | -23,328,000 | -23,996,000 | -25,032,000 | -25,299,000 | -4,404,000 | -66,463,500 | -23,699,000 | -28,960,000 | -14,130,000 |
EBT Margin | 455.0% | 0.15 | -0.04 | -0.37 | -0.89 | -1.04 | -1.87 | -2.84 | -3.02 | -3.26 | -3.11 | -3.16 | -3.14 | -3.28 | - | - | - | - | - | - | - | - |
Net Income | 1547.7% | 13,791,000 | 837,000 | 2,992,000 | -1,087,000 | -3,311,000 | -8,775,500 | -29,064,000 | -29,496,000 | -31,981,000 | -34,823,000 | -30,982,000 | -26,736,000 | -23,328,000 | -23,996,000 | -25,032,000 | -25,299,000 | 9,507,000 | -35,455,000 | -23,699,000 | -28,960,000 | -14,124,000 |
Net Income Margin | 2567.5% | 0.14 | -0.01 | -0.11 | -0.53 | -1.04 | -1.87 | -2.84 | -3.02 | -3.26 | -3.11 | -3.16 | -3.14 | -3.28 | - | - | - | - | - | - | - | - |
Free Cashflow | -17.7% | -26,160,000 | -22,229,000 | -18,252,000 | -25,695,000 | 9,301,000 | -1,575,000 | -34,255,000 | -34,649,000 | -42,049,000 | -31,437,000 | -29,968,000 | -28,313,000 | -30,922,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -8.5% | 185 | 202 | 221 | 209 | 235 | 261 | 226 | 260 | 297 | 339 | 371 | 402 | 434 | 359 | 375 | 402 | 437 | 341 | 373 | 405 | 445 |
Current Assets | -8.6% | 167 | 183 | 201 | 188 | 212 | 237 | 200 | 233 | 268 | 310 | 241 | 271 | 400 | 324 | 340 | 367 | 400 | 303 | 335 | 367 | 405 |
Cash Equivalents | 110.7% | 36.00 | 17.00 | 26.00 | 58.00 | 56.00 | 194 | 95.00 | 129 | 163 | 206 | 236 | 256 | 330 | 192 | 177 | 291 | 143 | 188 | 165 | 149 | 190 |
Net PPE | -9.9% | 4.00 | 4.00 | 4.00 | 4.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 |
Goodwill | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Liabilities | -13.2% | 216 | 249 | 272 | 294 | 321 | 347 | 307 | 315 | 327 | 340 | 341 | 344 | 353 | 366 | 327 | 344 | 367 | 290 | 290 | 304 | 322 |
Current Liabilities | -7.3% | 145 | 156 | 147 | 141 | 151 | 153 | 124 | 95.00 | 87.00 | 78.00 | 68.00 | 60.00 | 65.00 | 68.00 | 102 | 99.00 | 106 | 86.00 | 76.00 | 79.00 | 96.00 |
Shareholder's Equity | 33.2% | -31.68 | -47.45 | - | - | -86.64 | -85.75 | 28.00 | 49.00 | 68.00 | 89.00 | 30.00 | 58.00 | 81.00 | 50.00 | 48.00 | 59.00 | 70.00 | 25.00 | 82.00 | 102 | 123 |
Retained Earnings | 1.9% | -709 | -723 | -724 | -727 | -726 | -722 | -714 | -685 | -655 | -623 | -588 | -557 | -531 | -507 | -435 | -420 | -405 | -442 | -381 | -358 | -329 |
Additional Paid-In Capital | 0.3% | 678 | 676 | 673 | 642 | 640 | 637 | 634 | 632 | 627 | 623 | 619 | 616 | 612 | 500 | 484 | 480 | 474 | 468 | 464 | 459 | 452 |
Shares Outstanding | -100.0% | - | 67.00 | 81.00 | 66.00 | 66.00 | 66.00 | 66.00 | 66.00 | 65.00 | 65.00 | 64.00 | 63.00 | 61.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 114 | - | - | - | 118 | - | - | - | 408 | - | - | - | 379 | - | - | - | 502 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -18.6% | -26,045 | -21,963 | -18,243 | -25,178 | 9,349 | -1,393 | -33,845 | -34,237 | -41,313 | -31,192 | -29,700 | -28,199 | -29,940 | -17,427 | -24,678 | 97,101 | -49,737 | -29,479 | -23,319 | -48,653 | -39,029 |
Share Based Compensation | -25.3% | 1,907 | 2,552 | 1,226 | 2,371 | 2,409 | 2,570 | 2,695 | 4,490 | 3,370 | 3,544 | 3,164 | 3,425 | 3,034 | 3,419 | 3,841 | 3,513 | 4,013 | 4,111 | 4,343 | 5,454 | 5,192 |
Cashflow From Investing | 248.9% | 44,885 | 12,866 | -42,938 | 26,040 | -146,642 | 99,818 | -410 | -412 | -736 | -245 | 9,734 | -46,012 | 59,012 | 19,455 | -90,067 | 49,453 | 2,441 | 52,857 | 38,510 | 6,940 | -18,606 |
Cashflow From Financing | -28.7% | 174 | 244 | 29,669 | 317 | - | 190 | - | 451 | 7.00 | 683 | 104 | 691 | 108,735 | 13,021 | 167 | 1,548 | 2,157 | 401 | 63.00 | 698 | 465 |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||
Revenues | $ 41,463 | $ 23,499 |
Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
Operating expenses: | ||
Research and development | $ 22,052 | $ 21,175 |
General and administrative | 7,754 | 7,977 |
Total operating expenses | 29,806 | 29,152 |
Income (Loss) from operations | 11,657 | (5,653) |
Interest income | 2,194 | 2,327 |
Other (expense) income, net | (11) | 15 |
Income (Loss) before income taxes | 13,840 | (3,311) |
Provision for income taxes | 49 | 0 |
Net Income (loss) | 13,791 | (3,311) |
Other comprehensive income (loss): | ||
Unrealized (loss) gain on investments, net of tax | (105) | 16 |
Total comprehensive income (loss) | $ 13,686 | $ (3,295) |
Net income (loss) per share, Basic | $ 0.17 | $ (0.05) |
Net income (loss) per share, Diluted | $ 0.17 | $ (0.05) |
Shares used to compute net income (loss) per share, Basic | 82,029,466 | 66,248,992 |
Shares used to compute net income (loss) per share, Diluted | 82,630,020 | 66,248,992 |
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 | [1] | Mar. 31, 2023 | Dec. 31, 2022 | ||
---|---|---|---|---|---|---|---|
Current assets: | |||||||
Cash and cash equivalents | $ 36,185 | $ 17,171 | |||||
Short-term investments | 114,099 | 157,338 | |||||
Accounts receivable | 13,177 | 3,432 | |||||
Prepaid expenses and other current assets | 3,786 | 4,995 | |||||
Total current assets | 167,247 | 182,936 | |||||
Property and equipment, net | 3,567 | 3,958 | |||||
Intangible assets, net | 693 | 729 | |||||
Goodwill | 949 | 949 | |||||
Restricted cash | 917 | 917 | |||||
Operating lease right-of-use asset | 11,234 | 12,220 | |||||
Other assets | 80 | 83 | |||||
Total assets | 184,687 | 201,792 | |||||
Current liabilities: | |||||||
Accounts payable | 1,964 | 1,458 | |||||
Accrued liabilities | 14,220 | 17,599 | |||||
Operating lease liabilities - short term | 4,724 | 4,589 | |||||
Deferred revenue, current portion | 123,628 | 132,267 | |||||
Total current liabilities | 144,536 | 155,913 | |||||
Deferred revenue, net of current portion | 59,743 | 80,048 | |||||
Operating lease liabilities - long term | 8,148 | 9,385 | |||||
Other long-term liabilities | 3,940 | 3,893 | |||||
Total liabilities | 216,367 | 249,239 | |||||
Commitments and contingencies (Note 9) | |||||||
Stockholders' deficit: | |||||||
Convertible preferred stock | 0 | 0 | |||||
Common stock | 1 | 1 | |||||
Additional paid-in capital | 677,986 | 675,905 | |||||
Accumulated other comprehensive (loss) income | (10) | 95 | |||||
Accumulated deficit | (709,657) | (723,448) | |||||
Total stockholders' deficit | (31,680) | (47,447) | $ (86,637) | $ (85,751) | |||
Total liabilities and stockholders' deficit | $ 184,687 | $ 201,792 | |||||
|